什科宁在B16F10黑色素瘤中引起非亡性细胞死亡
Haleema Ahmad1, Megan S Crotts1, Jena C Jacobs1
1Department of Biochemistry, A.T. Still University, 800 West Jefferson Street, Kirksville, MO 63501, USA.
Anti-cancer agents in medicinal chemistry
|July 2, 2023
概括
中国草药Shikonin通过诱导非亡性细胞死亡途径 (necroptosis) 有效地减少黑色素瘤细胞的生长. 这项研究探讨了shikoninonin.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 黑色素瘤对常规化疗表现出耐药性,需要探索替代细胞死亡机制.
- 非亡细胞死亡途径对于克服黑色素瘤治疗阻力至关重要.
研究的目的:
- 为了研究中国草药石康宁对B16F10黑色素瘤细胞的抗癌作用.
- 为了阐明由shikonin在黑色素瘤细胞中诱导的特定细胞死亡途径.
主要方法:
- 通过MTT试验评估细胞活力;使用BrdU标记分析细胞增殖.
- 流细胞测量用于确定细胞死亡类型;通过单一丹西尔卡达维林染色测量自水平.
- 西方涂抹分析了亡标记物 (CHOP,RIP1,pRIP1);用MitoTracker检查了线粒体密度.
主要成果:
- 石康宁显著降低了B16F10黑色素瘤细胞的生长和扩散,以剂量依赖的方式.
- 表明生死,自和活性氧物种 (ROS) 在什科宁的作用机制中的参与.
- 石康宁治疗上调了与压力相关的蛋白质 (CHOP,RIP,pRIP) 并影响了线粒体密度.
结论:
- 在B16F10黑色素瘤细胞中,西康宁有效诱导亡作为主要细胞死亡机制.
- 希科宁的抗黑色素瘤活性与诱导ROS产生和自有关.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.1K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.7K
相关概念视频
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
